Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F182112, Isatuximab, and Lenalidomide in Newly Diagnosed Multiple Myeloma
NCT07828522Phase 2Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Oct 2026
- Primary completion
- Oct 2027
01
Overview
Phase 2, open-label trial of F182112 in multiple myeloma (MM), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Incidence and outcomes of treatment-emergent adverse events and serious adverse events at 6 months. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
F182112
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07828522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07828522.